COMMUNIQUÉS West-GlobeNewswire

Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
26/12/2017
SAN DIEGO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for the Company’s [...]
India Globalization Capital to use Blockchain to Address Issues Specific to the Medical Cannabis Industry
26/12/2017
BETHESDA, Md., Dec. 26, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), today announces that it will leverage its existing team of technology and healthcare experts to develop methods [...]
Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26/12/2017
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]
Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit
26/12/2017
Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders LOS ANGELES, CA, Dec. 26, 2017 (GLOBE NEWSWIRE [...]
FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia
26/12/2017
SAN DIEGO and TORONTO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO ) (TSX: APS ) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CG’806 [...]
Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
26/12/2017
- Ivosidenib Has Potential to be a First-in-Class Therapy for Patients with R/R AML and an IDH1 mutation - - Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for AG-270 Targeting MTAP- [...]
Transactions in relation to share buyback program
26/12/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
NANOBIOTIX : 2017 review and 2018 expected milestones
26/12/2017
Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]
NANOBIOTIX : revue de l'année 2017 et perspectives 2018
26/12/2017
Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]
NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial
26/12/2017
FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]
NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix
26/12/2017
LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.
23/12/2017
Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD Positions Summit as a Leader in Research & Development [...]
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
23/12/2017
Positions Summit as a Leader in Research & Development of New Classes of Antibiotics Enhances Summit’s Broader Business in Rare and Infectious Diseases Supports Mission to Discover and Develop Therapies for Patients [...]
MedMira Reports First Quarter Results
23/12/2017
HALIFAX, Nova Scotia, Dec. 22, 2017 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSX-V: MIR ), reported today on its financial results for the quarter ended October 31, 2017. Profit and Loss Highlights Revenue: In Q1 [...]
Helius Medical Technologies Announces Closing of First Tranche of Private Placement
23/12/2017
NEWTOWN, Pa., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX: HSM ) (TSX:HSM.WT) (OTCQB:HSDT) (“Helius” or the “Company”) , a medical technology company focused on neurological wellness, is [...]
MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna
23/12/2017
PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a diagnostics company that enables the development and commercialization of precision medicines in oncology, announced [...]
Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel
22/12/2017
SAN FRANCISCO and TEL AVIV, Israel, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the " Company " or " Kalytera ") today announced that the TSX Venture Exchange (“ TSXV [...]
Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)
22/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA ) today announced that the U.S. Food and Drug Administration (FDA) will extend its review of the Biologics [...]
MPX Closes Oversubscribed Private Placement Offering of $26.5 Million
22/12/2017
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Dec. 22, 2017 (GLOBE NEWSWIRE) -- (CSE:MPX) (OTC:MPXEF) MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE: [...]

Pages